Requires any sponsor of a clinical trial in this state, including but not limited to, a pharmaceutical drug manufacturer, pharmaceutical drug wholesaler, academic medical center, voluntary group, federal agency or health care provider, that applies for a state grant to conduct such clinical trial, to conspicuously post certain information about such clinical trial on the department's website.
Summary
Bill A05151 amends the public health law to require that any sponsor of a clinical trial in New York, which applies for state grant funding, must publicly disclose specific information about the trial. This includes details such as the names of sponsors, the purpose of the trial, the design and methodology, and potential adverse effects of the pharmaceutical products being tested. The bill mandates that this information be posted on both the department's website and the websites of the health care providers conducting the trials, ensuring transparency and accessibility for the public.
Impact
The bill will enhance transparency in clinical trials conducted in New York by mandating the disclosure of critical information that can help potential participants make informed decisions. It will affect pharmaceutical companies, academic institutions, and health care providers involved in clinical trials, as they will need to comply with the new posting requirements. Additionally, it may lead to increased public trust in clinical research by providing clearer insights into the trials being conducted.
Sentiment
The sentiment around Bill A05151 appears to be generally supportive, as it aims to improve transparency in clinical trials. However, there may be concerns regarding the administrative burden it places on sponsors and health care providers to comply with the new requirements. Discussions in committees have not yet been documented, but the intent to enhance public knowledge about clinical trials is likely to resonate positively with stakeholders and the public.
Contention
Notable points of contention may arise from pharmaceutical companies and health care providers regarding the potential implications of disclosing sensitive information about clinical trials. Some may argue that the requirements could deter sponsors from applying for state grants due to the increased transparency and potential exposure of proprietary information. There may also be discussions about the balance between public interest and the confidentiality of clinical research.
Same As
Requires any sponsor of a clinical trial in this state, including but not limited to, a pharmaceutical drug manufacturer, pharmaceutical drug wholesaler, academic medical center, voluntary group, federal agency or health care provider, that applies for a state grant to conduct such clinical trial, to conspicuously post certain information about such clinical trial on the department's website.
Requires any sponsor of a clinical trial in this state, including but not limited to, a pharmaceutical drug manufacturer, pharmaceutical drug wholesaler, academic medical center, voluntary group, federal agency or health care provider, that applies for a state grant to conduct such clinical trial, to conspicuously post certain information about such clinical trial on the department's website.
Requires any sponsor of a clinical trial in this state, including but not limited to, a pharmaceutical drug manufacturer, pharmaceutical drug wholesaler, academic medical center, voluntary group, federal agency or health care provider, that applies for a state grant to conduct such clinical trial, to conspicuously post certain information about such clinical trial on the department's website.
Designates third full week of May of each year as "Clinical Trials Awareness Week" and May 20 of each year as "Clinical Trials Volunteers Appreciation Day" in NJ.